USD 2.61
↑ 0.08 (3.16%)
| ticker | 1 day return % | 1 week return % | 1 month return % | 3 months return % | 6 months return % | 1 year return % | 3 years return % | 5 years return % | 10 years return % | maximum return % |
|---|---|---|---|---|---|---|---|---|---|---|
| ABOS | 3.2 | -18.2 | 11.1 | 3.6 | -29.3 | 22.5 | -78.0 | -87.0 | -87.0 | -87.0 |
| S&P 500 | -0.6 | -0.5 | 1.5 | 9.1 | 13.4 | 32.3 | 27.0 | 92.1 | 191.7 | 33587.3 |
Our interactive price chart includes various drawing tools to help you analyze the product more effectively. Below is a quick guide on how to use these tools: Full Guideline
Feel free to experiment with these tools to enhance your technical analysis. Remember, any drawings you make are temporary and will be lost upon refreshing the page unless saved as an image using the 'Camera' icon.
Get instant AI-powered professional insights on prices:
💡Generate AI Technical Analysis ReportA Multi-Interval Candlestick Chart displays the price movements of an asset over different time intervals. Each candlestick represents the open, high, low, and close prices for a specific interval. The chart can be used to identify trends and patterns in price movements.
| Attribute | Value |
|---|---|
| symbol | ABOS |
| name | Acumen Pharmaceuticals, Inc. |
| price | 2.61 |
| changes percentage | 3.1621 |
| change | 0.08 |
| day low | 2.41 |
| day high | 2.66 |
| year high | 5.09 |
| year low | 2.08 |
| market cap | 156808278 |
| price avg 50 | 2.6079 |
| price avg 200 | 3.078725 |
| exchange | NASDAQ |
| volume | 194105 |
| avg volume | 187296 |
| open | 2.57 |
| previous close | 2.53 |
| eps | -1.11 |
| pe | -2.35 |
| earnings announcement | 2024-11-12T05:00:00.000+0000 |
| shares outstanding | 60079800 |
| timestamp | 2024-11-14 21:00:01 |
We derive the score of a company's financial statements by evaluating the weighted average sentiment across key within the statements. The cumulative score, normalized to a sum of 1, serves as a metric for assessing the company's performance during the specified period. A higher score indicates stronger performance. However, it's crucial to note that while this score provides valuable insights, it is just one of many factors to consider when making informed investment decisions. A holistic evaluation, considering various aspects of the company's financial health and market conditions, is essential for a well-rounded investment strategy.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001576885 | |||
| revenue | 0 | 0 | NaN |
| gross profit | -42318000 | -169000 | -24940.24 |
| gross profit ratio | 0 | 0 | NaN |
| research and development expenses | 42318000 | 32361000 | 30.77 |
| operating expenses | 61138000 | 45237000 | 35.15 |
| interest income | 10791000 | 2392000 | 351.13 |
| interest expense | -581000 | -2381000 | 75.60 |
| ebitda | -51606000 | -42687000 | -20.89 |
| ebitdaratio | 0 | 0 | NaN |
| operating income | -61138000 | -45237000 | -35.15 |
| operating income ratio | 0 | 0 | NaN |
| net income | -52371000 | -40475000 | -29.39 |
| net income ratio | 0 | 0 | NaN |
| eps | -1.08 | -1 | -8.00 |
Gross Profit: Gross Profit decreased to -42 million in 2023 from 0 million in 2022 representing a change of -24940.24%. This indicates a sales profitability decline, which is a negative sign for the company.
Operating Expenses: Operating Expenses increased to 61 million in 2023 from 45 million in 2022 representing a change of 35.15%. The increase in operating expenses can be attributed to various factors such as marketing, administrative costs, and investments in infrastructure. It's important to monitor if these expenses are growing at a sustainable rate compared to revenue.
Earnings per Share (EPS): EPS increased to -1.08 in 2023 from -1.08 in 2022 representing a change of -8.0%. This indicates that the company's earnings are decreasing and it is becoming less profitable on a per-share basis.
Research and Development (R&D) Expenses: R&D Expenses increased to 42 million in 2023 from 32 million in 2022 representing a change of 30.77%. This shows that the company continues to invest in innovation and product development, which is crucial for long-term growth.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) increased to -52 million in 2023 from -43 million in 2022 representing a change of -20.89%. The increase in EBITDA indicates improved operational efficiency and profitability.
Operating Income: Operating income increased to -61 million in 2023 from -45 million in 2022 representing a change of -35.15%. The increase in operating income indicates better operational performance and increased profitability.
Net Income: Net income increased to -52 million in 2023 from -40 million in 2022 representing a change of -29.39%. The increase in net income shows improved profitability and indicates that the company is generating more profit for each dollar of revenue.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001576885 | |||
| revenue | 0 | 0 | NaN |
| gross profit | 0 | -45000 | 100.00 |
| gross profit ratio | 0 | 0 | NaN |
| research and development expenses | 27247000 | 19533000 | 39.49 |
| operating expenses | 32265000 | 24381000 | 32.34 |
| interest income | 3504000 | 3816000 | -8.18 |
| interest expense | -1027000 | 1004000 | -202.29 |
| ebitda | -32265000 | -19488000 | -65.56 |
| ebitdaratio | 0 | 0 | NaN |
| operating income | -32265000 | -24381000 | -32.34 |
| operating income ratio | 0 | 0 | NaN |
| net income | -29765000 | -20537000 | -44.93 |
| net income ratio | 0 | 0 | NaN |
| eps | -0.5 | -0.34 | -47.06 |
Gross Profit: Gross Profit increased to 0 million in 2024Q3 from 0 million in 2024Q2 representing a change of 100.0%. This indicates a sales profitability growth, which is a positive sign for the company.
Research and Development (R&D) Expenses: R&D Expenses increased to 27 million in 2024Q3 from 20 million in 2024Q2 representing a change of 39.49%. This shows that the company continues to invest in innovation and product development, which is crucial for long-term growth.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) increased to -32 million in 2024Q3 from -19 million in 2024Q2 representing a change of -65.56%. The increase in EBITDA indicates improved operational efficiency and profitability.
Operating Income: Operating income increased to -32 million in 2024Q3 from -24 million in 2024Q2 representing a change of -32.34%. The increase in operating income indicates better operational performance and increased profitability.
Net Income: Net income increased to -30 million in 2024Q3 from -21 million in 2024Q2 representing a change of -44.93%. The increase in net income shows improved profitability and indicates that the company is generating more profit for each dollar of revenue.
Operating Expenses: Operating Expenses increased to 32 million in 2024Q3 from 24 million in 2024Q2 representing a change of 32.34%. The increase in operating expenses can be attributed to various factors such as marketing, administrative costs, and investments in infrastructure. It's important to monitor if these expenses are growing at a sustainable rate compared to revenue.
Earnings per Share (EPS): EPS increased to -0.5 in 2024Q3 from -0.5 in 2024Q2 representing a change of -47.06%. This indicates that the company's earnings are decreasing and it is becoming less profitable on a per-share basis.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001576885 | |||
| total assets | 310125000 | 196587000 | 57.75 |
| total liabilities | 43152000 | 7812000 | 452.38 |
| total equity | 266973000 | 188775000 | 41.42 |
| cash and cash equivalents | 66886000 | 130101000 | -48.59 |
| short term investments | 176636000 | 47504000 | 271.83 |
| long term investments | 62553000 | 15837000 | 294.98 |
| total current assets | 246615000 | 180329000 | 36.76 |
| total non current assets | 63510000 | 16258000 | 290.64 |
| total current liabilities | 12971000 | 7812000 | 66.04 |
| total non current liabilities | 30181000 | 0 | NaN |
| common stock | 6000 | 4000 | 50.00 |
| retained earnings | -222798000 | -170427000 | -30.73 |
| total debt | 28487000 | 105000 | 27030.48 |
Total Assets: Total Assets increased to 310 million in 2023 from 197 million in 2022 representing a change of 57.75%. Suggesting a growth in asset holdings.
Total Equity: Total Equity increased to 267 million in 2023 from 189 million in 2022 representing a change of 41.42%. This indicates an increase in shareholders' equity.
Short Term Investments: Short Term Investments increased to 177 million in 2023 from 48 million in 2022 representing a change of 271.83%. This indicates an increase in short-term investment holdings.
Total Current Assets: Total Current Assets increased to 247 million in 2023 from 180 million in 2022 representing a change of 36.76%. This indicates a better liquidity position.
Common Stock: Common Stock increased to 0 in 2023 from 0 in 2022 representing a change of 50.0%. This indicates an increase in ownership interest.
Total Liabilities: Total Liabilities increased to 43 million in 2023 from 8 million in 2022 representing a change of 452.38%. This indicates an increase in overall liabilities.
Cash And Cash Equivalents: Cash And Cash Equivalents decreased to 67 million in 2023 from 130 million in 2022 representing a change of -48.59%. This indicates a decrease in available liquid assets.
Total Current Liabilities: Total Current Liabilities increased to 13 million in 2023 from 8 million in 2022 representing a change of 66.04%. This indicates a higher short-term debt burden.
Retained Earnings: Retained Earnings decreased to -223 million in 2023 from -170 million in 2022 representing a change of -30.73%. This indicates an accumulated losses.
Total Debt: Total Debt increased to 28 million in 2023 from 0 million in 2022 representing a change of 27030.48%. This indicates an increase in overall debt burden.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001576885 | |||
| total assets | 266975000 | 288913000 | -7.59 |
| total liabilities | 49773000 | 44966000 | 10.69 |
| total equity | 217202000 | 243947000 | -10.96 |
| cash and cash equivalents | 33184000 | 67955000 | -51.17 |
| short term investments | 167159000 | 192517000 | -13.17 |
| long term investments | 58552000 | 20908000 | 180.05 |
| total current assets | 207632000 | 266915000 | -22.21 |
| total non current assets | 59343000 | 21998000 | 169.77 |
| total current liabilities | 19914000 | 15367000 | 29.59 |
| total non current liabilities | 29859000 | 29599000 | 0.88 |
| common stock | 6000 | 6000 | 0.00 |
| retained earnings | -287973000 | -258208000 | -11.53 |
| total debt | 29988000 | 28214000 | 6.29 |
Total Assets: Total Assets decreased to 267 million in 2024Q3 from 289 million in 2024Q2 representing a change of -7.59%. Suggesting a decrease in asset holdings.
Total Liabilities: Total Liabilities increased to 50 million in 2024Q3 from 45 million in 2024Q2 representing a change of 10.69%. This indicates an increase in overall liabilities.
Total Equity: Total Equity decreased to 217 million in 2024Q3 from 244 million in 2024Q2 representing a change of -10.96%. This indicates a decrease in shareholders' equity.
Cash And Cash Equivalents: Cash And Cash Equivalents decreased to 33 million in 2024Q3 from 68 million in 2024Q2 representing a change of -51.17%. This indicates a decrease in available liquid assets.
Short Term Investments: Short Term Investments decreased to 167 million in 2024Q3 from 193 million in 2024Q2 representing a change of -13.17%. This indicates a decrease in short-term investment holdings.
Total Current Assets: Total Current Assets decreased to 208 million in 2024Q3 from 267 million in 2024Q2 representing a change of -22.21%. This indicates a worsen liquidity position.
Total Current Liabilities: Total Current Liabilities increased to 20 million in 2024Q3 from 15 million in 2024Q2 representing a change of 29.59%. This indicates a higher short-term debt burden.
Retained Earnings: Retained Earnings decreased to -288 million in 2024Q3 from -258 million in 2024Q2 representing a change of -11.53%. This indicates an accumulated losses.
Total Debt: Total Debt increased to 30 million in 2024Q3 from 28 million in 2024Q2 representing a change of 6.29%. This indicates an increase in overall debt burden.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001576885 | |||
| net change in cash | -62982000 | 7939000 | -893.32 |
| operating cash flow | -43064000 | -35153000 | -22.50 |
| free cash flow | -43085000 | -35314000 | -22.01 |
| capital expenditure | -21000 | -161000 | 86.96 |
| depreciation and amortization | 184000 | 169000 | 8.88 |
| deferred income tax | 0 | 0 | NaN |
| stock based compensation | 6145000 | 3061000 | 100.75 |
| accounts payables | -261000 | 552000 | -147.28 |
| inventory | 0 | 0 | NaN |
| acquisitions net | 0 | -39346 | 100.00 |
| investments in property plant and equipment | -21000 | -161000 | 86.96 |
| net cash used for investing activites | -171671000 | 39185000 | -538.10 |
| debt repayment | 30000000 | 0 | NaN |
| common stock issued | 121904000 | 3792000 | 3114.77 |
| common stock repurchased | 0 | 0 | NaN |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | 151753000 | 3907000 | 3784.13 |
| cash at end of period | 67119000 | 130101000 | -48.41 |
| accounts receivables | 0 | 0 | NaN |
| cash at beginning of period | 130101000 | 122162000 | 6.50 |
Net Change in Cash: Net Change in Cash decreased to -63 million in 2023 from 8 million in 2022 representing a change of -893.32%. Indicating a declined ability to generate cash from the company's operations or its cash flow position.
Operating Cash Flow: Operating Cash Flow decreased to -43 million in 2023 from -35 million in 2022 representing a change of -22.5%. This indicates that the company generated less cash from its core business operations.
Free Cash Flow: Free Cash Flow decreased to -43 million in 2023 from -35 million in 2022 representing a change of -22.01%. This indicates a decrease in cash generated after accounting for capital expenditures.
Capital Expenditure: Capital Expenditure increased to 0 million in 2023 from 0 million in 2022 representing a change of 86.96%. This indicates an increase in the cash outflow required for acquiring or improving long-term assets.
Stock-Based Compensation: Stock-Based Compensation increased to 6 million in 2023 from 3 million in 2022 representing a change of 100.75%. This indicates increased expenses, which is generally considered a negative sign from a financial perspective.
Accounts Payables: The absolute value of Accounts Payables decreased to 0 million in 2023 from 1 million in 2022 representing a change of -147.28%. This indicates that the company has reduced its outstanding obligations to its suppliers.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001576885 | |||
| operating cash flow | -24596000 | -16545000 | -48.66 |
| free cash flow | -24596000 | -16550000 | -48.62 |
| capital expenditure | 0 | -5000 | 100.00 |
| depreciation and amortization | -4639000 | 45000 | -10408.89 |
| deferred income tax | 0 | 0 | NaN |
| stock based compensation | 2338000 | 2470000 | -5.34 |
| accounts receivables | 0 | 0 | NaN |
| accounts payables | -1860000 | 1123000 | -265.63 |
| inventory | 0 | 0 | NaN |
| acquisitions net | 0 | 0 | NaN |
| investments in property plant and equipment | 0 | -5000 | 100.00 |
| net cash used for investing activites | -10132000 | 37699000 | -126.88 |
| debt repayment | 0 | 0 | NaN |
| common stock issued | 188000 | -128000 | 246.88 |
| common stock repurchased | 0 | 0 | NaN |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | -42000 | -128000 | 67.19 |
| net change in cash | -34535000 | 21025000 | -264.26 |
| cash at end of period | 33420000 | 67955000 | -50.82 |
| cash at beginning of period | 67955000 | 46930000 | 44.80 |
Net Change in Cash: Net Change in Cash decreased to -35 million in 2024Q3 from 21 million in 2024Q2 representing a change of -264.26%. Indicating a declined ability to generate cash from the company's operations or its cash flow position.
Operating Cash Flow: Operating Cash Flow decreased to -25 million in 2024Q3 from -17 million in 2024Q2 representing a change of -48.66%. This indicates that the company generated less cash from its core business operations.
Free Cash Flow: Free Cash Flow decreased to -25 million in 2024Q3 from -17 million in 2024Q2 representing a change of -48.62%. This indicates a decrease in cash generated after accounting for capital expenditures.
Capital Expenditure: Capital Expenditure increased to 0 million in 2024Q3 from 0 million in 2024Q2 representing a change of 100.0%. This indicates an increase in the cash outflow required for acquiring or improving long-term assets.
Accounts Payables: The absolute value of Accounts Payables increased to 2 million in 2024Q3 from 1 million in 2024Q2 representing a change of -265.63%. This indicates that the company has increased its outstanding obligations to its suppliers.
Stock-Based Compensation: Stock-Based Compensation decreased to 2 million in 2024Q3 from 2 million in 2024Q2 representing a change of -5.34%. This indicates decreased expenses, which is generally considered a positive sign from a financial perspective.
We save you time by utilizing Generative AI to summarize earnings transcripts. Our summaries provide a clear insight into the company's current performance, future outlook, and overall sentiment expressed during the call. Click on below links to explore more.
Note: The years mentioned below are fiscal years in accounting.
Q3 2024 Earnings call transcript
EPS represents the portion of a company's profit allocated to each outstanding share of common stock. A higher EPS is generally favorable, indicating stronger profitability on a per-share basis.
Positive EPS: A positive EPS signifies that a company is profitable, it is generally viewed positively, supporting stock value and investor confidence.
Negative EPS: Indicates that a company is operating at a loss, which could lead to negative sentiment, potential stock depreciation, and concerns about the company's financial health.
The Next Earning Date represents when the company plans to release its next set of financial results.
An upward trend in EPS suggests consistent growth in earnings, often leading to increased investor confidence. A downward trend may indicate a decline in earnings, potentially decreasing investor confidence and stock value. Fluctuating EPS suggests unpredictable financial performance, warranting cautious investor analysis.
Earnings surprise occurs when a company's actual earnings differ from analysts' expectations. A positive earnings surprise typically reflects better-than-expected performance, potentially leading to stock appreciation. Conversely, a negative earnings surprise can result in stock depreciation. An earnings surprise of zero means the earnings met expectations, which typically has a neutral impact on stock price.
Discover detailed analyst recommendations for stocks, including categories such as Buy, Hold, Sell, Strong Buy, and Strong Sell. These insights are based on thorough analysis of financial and market factors. The consensus is calculated by assigning a numerical score to each recommendation. These scores are then weighted and averaged over a specified period to provide a comprehensive view of the stock's outlook, with the final score determining the overall consensus.
| 2023-12-31 | 2022-12-31 | Y/Y change % | |
|---|---|---|---|
| FY | |||
| calendar year | 2023 | 2022 | NaN |
| revenue per share | 0 | 0 | NaN |
| net income per share | -1.08 | -1.0 | -8.34 |
| operating cash flow per share | -0.89 | -0.87 | -2.57 |
| free cash flow per share | -0.89 | -0.87 | -2.16 |
| cash per share | 5.02 | 4.37 | 14.81 |
| book value per share | 5.51 | 4.65 | 18.42 |
| tangible book value per share | 5.51 | 4.65 | 18.42 |
| shareholders equity per share | 5.51 | 4.65 | 18.42 |
| interest debt per share | 0.57 | -0.06 | 1116.17 |
| market cap | 186205440 | 219250454.4 | -15.07 |
| enterprise value | 147806440 | 89254454.4 | 65.60 |
| pe ratio | -3.56 | -5.42 | 34.36 |
| price to sales ratio | 0 | 0 | NaN |
| pocfratio | -4.32 | -6.24 | 30.67 |
| pfcf ratio | -4.32 | -6.21 | 30.39 |
| pb ratio | 0.7 | 1.16 | -39.95 |
| ptb ratio | 0.7 | 1.16 | -39.95 |
| ev to sales | 0 | 0 | NaN |
| enterprise value over ebitda | -2.86 | -2.09 | -36.98 |
| ev to operating cash flow | -3.43 | -2.54 | -35.18 |
| ev to free cash flow | -3.43 | -2.53 | -35.73 |
| earnings yield | -0.28 | -0.18 | -52.35 |
| free cash flow yield | -0.23 | -0.16 | -43.66 |
| debt to equity | 0.11 | 0.0 | 18892.54 |
| debt to assets | 0.09 | 0.0 | 16926.45 |
| net debt to ebitda | 0.74 | 3.05 | -75.57 |
| current ratio | 19.01 | 23.08 | -17.64 |
| interest coverage | 105.23 | 19.0 | 453.86 |
| income quality | 0.82 | 0.82 | 0.25 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 0 | 0 | NaN |
| research and ddevelopement to revenue | 0 | 0 | NaN |
| intangibles to total assets | 0 | 0 | NaN |
| capex to operating cash flow | -0.0 | -0.0 | 89.35 |
| capex to revenue | 0 | 0 | NaN |
| capex to depreciation | 0.11 | 0.95 | -88.02 |
| stock based compensation to revenue | 0 | 0 | NaN |
| graham number | 11.57 | 10.21 | 13.27 |
| roic | -0.21 | -0.23 | 8.43 |
| return on tangible assets | -0.17 | -0.21 | 17.98 |
| graham net net | 4.14 | 4.18 | -1.11 |
| working capital | 233644000 | 172517000 | 35.43 |
| tangible asset value | 266973000 | 188775000 | 41.42 |
| net current asset value | 203463000 | 172517000 | 17.94 |
| invested capital | 234147000 | 172787000 | 35.51 |
| average receivables | 112500 | 0 | NaN |
| average payables | 1509500 | 1364000 | 10.67 |
| average inventory | 0 | 0 | NaN |
| days sales outstanding | 0 | 0 | NaN |
| days payables outstanding | 11.89 | 3542.01 | -99.66 |
| days of inventory on hand | 0 | 0 | NaN |
| receivables turnover | 0 | 0 | NaN |
| payables turnover | 30.69 | 0.1 | 29679.54 |
| inventory turnover | 0 | 0 | NaN |
| roe | -0.2 | -0.21 | 8.51 |
| capex per share | 0.0 | 0.0 | -89.08 |
ROE: Return on Equity (ROE) increased to -0.20 on 2023-12-31 from -0.21 on 2022-12-31, representing a change of 8.51%. However, ROE is <= 5%, suggesting that the company has not been generating high returns for its shareholders.
Current Ratio: Current Ratio decreased to 19.01 on 2023-12-31 from 23.08 on 2022-12-31, representing a change of -17.64%. The current ratio has been declining, suggesting a decrease in the company's short-term liquidity. Since it's above 3, indicating poor management of working capital.
PE Ratio: Price-to-Earnings (P/E) Ratio increased to -3.56 on 2023-12-31 from -5.42 on 2022-12-31, representing a change of 34.36%. Indicating an increase in the relative valuation of the company's stock.
Debt-to-Equity Ratio: Debt-to-Equity Ratio increased to 0.11 on 2023-12-31 from 0.00 on 2022-12-31, representing a change of 18892.54%. The debt-to-equity ratio has been increasing, indicating that the company has been relying more on debt financing. Higher leverage may increase financial risk. However, a ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
| 2024-09-30 Q3 | 2024-06-30 Q2 | Q/Q change % | |
|---|---|---|---|
| ABOS | |||
| calendar year | 2024 | 2024 | NaN |
| revenue per share | 0 | 0 | NaN |
| net income per share | -0.5 | -0.34 | -44.93 |
| operating cash flow per share | -0.41 | -0.28 | -48.66 |
| free cash flow per share | -0.41 | -0.28 | -48.62 |
| cash per share | 3.33 | 4.34 | -23.08 |
| book value per share | 3.62 | 4.06 | -10.96 |
| tangible book value per share | 3.62 | 4.06 | -10.90 |
| shareholders equity per share | 3.62 | 4.06 | -10.96 |
| interest debt per share | 0.48 | 0.48 | -0.13 |
| market cap | 148997849.44 | 142989871.64 | 4.20 |
| enterprise value | 145801849.44 | 103248871.64 | 41.21 |
| pe ratio | -1.25 | -1.74 | 28.10 |
| price to sales ratio | 0 | 0 | NaN |
| pocfratio | -6.06 | -8.64 | 29.91 |
| pfcf ratio | -6.06 | -8.64 | 29.89 |
| pb ratio | 0.69 | 0.59 | 17.03 |
| ptb ratio | 0.69 | 0.59 | 17.03 |
| ev to sales | 0 | 0 | NaN |
| enterprise value over ebitda | -4.52 | -5.3 | 14.71 |
| ev to operating cash flow | -5.93 | -6.24 | 5.01 |
| ev to free cash flow | -5.93 | -6.24 | 4.98 |
| earnings yield | -0.2 | -0.14 | -39.09 |
| free cash flow yield | -0.17 | -0.12 | -42.62 |
| debt to equity | 0.14 | 0.11 | 20.31 |
| debt to assets | 0.11 | 0.1 | 15.92 |
| net debt to ebitda | 0.1 | 2.04 | -95.14 |
| current ratio | 10.43 | 17.37 | -39.97 |
| interest coverage | 31.42 | -24.28 | 229.37 |
| income quality | 0.83 | 0.81 | 2.57 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 0 | 0 | NaN |
| research and ddevelopement to revenue | 0 | 0 | NaN |
| intangibles to total assets | 0 | 0.0 | -100.00 |
| capex to operating cash flow | 0 | -0.0 | 100.00 |
| capex to revenue | 0 | 0 | NaN |
| capex to depreciation | 0 | 0.11 | -100.00 |
| stock based compensation to revenue | 0 | 0 | NaN |
| graham number | 6.35 | 5.59 | 13.60 |
| roic | -0.13 | -0.09 | -45.59 |
| return on tangible assets | -0.11 | -0.07 | -56.74 |
| graham net net | 2.51 | 3.59 | -30.16 |
| working capital | 187718000 | 251548000 | -25.37 |
| tangible asset value | 217202000 | 243763000 | -10.90 |
| net current asset value | 157859000 | 221949000 | -28.88 |
| invested capital | 188103000 | 252162000 | -25.40 |
| average receivables | 53000 | 147500 | -64.07 |
| average payables | 3276500 | 3645000 | -10.11 |
| average inventory | 0 | 0 | NaN |
| days sales outstanding | 0 | 0 | NaN |
| days payables outstanding | 0 | 8422 | -100.00 |
| days of inventory on hand | 0 | 0 | NaN |
| receivables turnover | 0 | 0 | NaN |
| payables turnover | 0 | 0.01 | -100.00 |
| inventory turnover | 0 | 0 | NaN |
| roe | -0.14 | -0.08 | -62.78 |
| capex per share | 0 | 0.0 | -100.00 |
ROE: Return on Equity (ROE) decreased to -0.14 on 2024-09-30 Q3 from -0.08 on 2024-06-30 Q2, representing a change of -62.78%. Suggesting that the company has not been generating high returns for its shareholders.
Current Ratio: Current Ratio decreased to 10.43 on 2024-09-30 Q3 from 17.37 on 2024-06-30 Q2, representing a change of -39.97%. The current ratio has been declining, suggesting a decrease in the company's short-term liquidity. Since it's above 3, indicating poor management of working capital.
PE Ratio: Price-to-Earnings (P/E) Ratio increased to -1.25 on 2024-09-30 Q3 from -1.74 on 2024-06-30 Q2, representing a change of 28.10%. Indicating an increase in the relative valuation of the company's stock.
Debt-to-Equity Ratio: Debt-to-Equity Ratio increased to 0.14 on 2024-09-30 Q3 from 0.11 on 2024-06-30 Q2, representing a change of 20.31%. The debt-to-equity ratio has been increasing, indicating that the company has been relying more on debt financing. Higher leverage may increase financial risk. However, a ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
Negative Sentiment: Discounted Cash Flow value is 0.79 which is lower than current price 2.61, indicates the company may be overvalued.
| Market Capitalization | Enterprise Value | |
|---|---|---|
| Definition | The total market value of a company's outstanding shares | The total market value of a company, including its debt and other liabilities |
| Calculation | Current share price * Total number of outstanding shares | Market capitalization + Total debt - Cash and cash equivalents |
| Focus | Equity component of a company's value | Total economic value of a company |
| Usefulness | Assesses a company's size and growth potential based on investor sentiment | Provides a more comprehensive valuation that considers both equity and debt |
Analyzing dividends is a crucial aspect of investment evaluation, offering valuable insights into a company's financial health and its commitment to shareholder returns. Dividends represent a portion of a company's profits distributed to its shareholders, providing a steady income stream. We help you analyze dividends based on the indicators mentioned below:
• Investors often assess the average dividend amount, observing trends over time to gauge the company's stability and growth potential. A positive trend in average dividends indicates a consistent and potentially lucrative investment. Additionally, evaluating the trend of dividend increases provides insight into the company's financial strength and management's confidence in future earnings.
• Consistency in paying dividends is a reassuring sign, reflecting a company's reliability and commitment to shareholder value. For investors, dividends not only offer income but also contribute to the overall total return on investment.
• Companies with a history of regular and increasing dividends can attract income-focused investors seeking stable returns, making dividends a critical factor in building a well-rounded investment portfolio.
Interested in the overall sentiment for a particular period? Check out our news sentiment analysis tool.
Sentiment: Positive
Publish Date: 2024-11-12 13:17:06
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS ) Q3 2024 Results Conference Call November 12, 2024 8:00 AM ET Company Participants Alex Braun - Head of Investor Relations Dan O'Connell - Chief Executive Officer Matt Zuga - Chief Financial Officer, Chief Business Officer Dr. Jim Doherty - President, Chief Development Officer Dr. Eric Siemers - Chief Medical Officer. Conference Call Participants Mark Hitrik - Stifel Tom Shrader - BTIG Cameron Bozdog - BofA Securities Samantha Schaeffer - Cantor Fitzgerald Operator Hello, and welcome to Acumen Pharmaceuticals Q3 2024 Conference Call and Webcast.
Sentiment: Positive
Publish Date: 2024-11-11 16:00:00
NEWTON, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in a fireside chat at the Stifel Healthcare Conference on Monday, Nov. 18, 2024, at 11:30 a.m. ET.
Sentiment: Positive
Publish Date: 2024-11-06 16:00:00
NEWTON, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in a fireside chat at the UBS Global Healthcare Conference on Wednesday, Nov. 13, 2024, at 1:15 p.m. PT (4:15 p.m. ET).
Sentiment: Positive
Publish Date: 2024-10-31 08:05:00
NEWTON, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today presented updated data on a validated research-use plasma pTau217 assay to screen potential participants in the ongoing Phase 2 ALTITUDE-AD clinical trial of sabirnetug, at the 17th Annual Clinical Trials on Alzheimer's Disease (CTAD) conference. The study found that this enrichment screening approach is resulting in a higher proportion of participants who meet the amyloid PET or CSF-based inclusion criteria compared to Acumen's Phase 1 INTERCEPT-AD trial, which did not use this approach. Furthermore, the enrichment approach is resulting in a more efficient participant selection process that reduces unnecessary amyloid PET scans or lumbar puncture (LP) procedures among people who are not eligible to continue in screening.
Sentiment: Positive
Publish Date: 2024-10-23 08:00:00
- Presentation to focus on use of validated pTau217 assay in participant screening process for Phase 2 ALTITUDE-AD study of sabirnetug for early Alzheimer's disease
Sentiment: Positive
Publish Date: 2024-09-30 16:00:00
NEWTON, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in a fireside chat at the Bank of America CNS Therapeutics Virtual Conference on Monday, Oct. 7, 2024, at 8:00 a.m. ET.
Sentiment: Positive
Publish Date: 2024-09-25 16:00:00
NEWTON, Mass., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today announced that the Company will host a virtual R&D Day on Wednesday, Oct. 2 at 10:00 a.m. ET. The webcast will highlight Acumen's strategic vision, and focus on the mechanistic rationale, pre-clinical and clinical data that support further development of sabirnetug as a treatment for early AD.
Sentiment: Positive
Publish Date: 2024-09-03 16:00:00
NEWTON, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in a fireside chat at the H.C. Wainwright 26th Annual Global Investor Conference on Tuesday, Sept. 10, 2024, at 1:30 p.m. ET.
* The sentiment analysis presented is generated through an algorithm and may be subject to inaccuracies. Users are advised to corroborate key information and employ further analytical methods prior to making critical decisions.
Get instant AI-powered professional insights:
💡Generate AI Technical Analysis ReportUnderstand the chart below:
Interpret Technical Indicators
| Indicator | Bullish | Bearish |
|---|---|---|
| Price and EMA ⓘ | Price crosses above EMA | Price crosses below EMA |
| Short-Term vs Long-Term EMA ⓘ | Short EMA crosses above Long EMA | Short EMA crosses below Long EMA |
| Volume ⓘ | Increasing volume during price uptrend | Increasing volume during price downtrend |
| MACD ⓘ | MACD crosses above Signal Line | MACD crosses below Signal Line |
| RSI ⓘ | RSI is below 30 (oversold) and starts to rise above 30 | RSI is above 70 (overbought) and starts to decline below 70 |
| Candlestick Patterns ⓘ | Bullish candlestick patterns | Bearish candlestick patterns |
Copyright © 2024 Sirius Investors
All rights reserved
